News & Events about Xbiotech Inc.
3 months ago
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announcedtoday the enrollment of the first patient in a multicenter, ...
7 months ago
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic CancerAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-...
9 months ago
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announcedtoday that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de scurit du ...